In a study by Alunni-Fabbroni, M. et al., 2019 in 13 male HCC patients treated with sorafenib, one of the most frequently detected mutant genes was TMBIM6 (69.2% of patients). This evidence concerns the gene TMBIM6 and hepatocellular carcinoma.